Paracetamol / Cafeine / Codeine Biogaran (Paracetamol, Codeine Phosphate Hemihydrate, Anhydrous Caffeine)

Paracetamol reduces pain and fever by inhibiting cyclooxygenase enzymes in the central nervous system, which lowers prostaglandin production. Codeine is metabolised to morphine, activating μ‑opioid receptors to further diminish pain signals and dampen the cough reflex. Caffeine blocks adenosine receptors, offering mild central stimulation that enhances the overall analgesic effect and offsets codeine‑induced drowsiness.

The specific dose and dosing interval are determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal pain relief while minimizing risk, and patients should follow the prescriber’s instructions without deviation.

Use of this combination during pregnancy or lactation should only occur when clearly indicated and after a risk‑benefit assessment by the treating physician. Codeine crosses the placenta and may affect the newborn, and paracetamol should be limited to the lowest effective dose. Breastfeeding mothers should consult their doctor before use.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team verifies trade or institutional credentials, then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Compared with non‑opioid analgesics such as ibuprofen, the Paracetamol / Caffeine / Codeine combination offers stronger relief for moderate pain due to the opioid component, while also addressing fever and cough. However, it carries opioid‑related risks like dependence and respiratory depression, which are absent with purely non‑opioid agents. Choice of therapy depends on pain severity, patient comorbidities and safety considerations.

The tablets should be stored at room temperature, below 25 °C, in their original blister pack or container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

The medication is supplied as oral tablets intended for swallowing with a full glass of water. It is usually taken with or without food, as directed by the prescriber. Patients should avoid crushing or chewing the tablets unless specifically instructed, to maintain proper release characteristics.

The most critical risks include respiratory depression, especially in opioid‑naïve or elderly patients; severe liver injury from paracetamol overdose; allergic reactions such as anaphylaxis; and the potential for dependence or addiction with prolonged use of codeine. Prompt medical attention is required if breathing becomes shallow, skin jauns, or signs of an allergic response appear.

The combination is contraindicated in children under 12 years, patients with known hypersensitivity to any component, individuals with severe hepatic impairment, those with significant respiratory conditions (e.g., severe asthma or COPD), and patients with a history of opioid addiction. It should also be avoided in patients taking monoamine oxidase inhibitors or certain antidepressants without medical supervision.